Indications: Lenvatinib is prescribed for two types of cancers:

• Differentiated thyroid cancer (DTC) that has recurred locally or spread to other parts of the body, and is progressive despite previous radioactive iodine treatment.
• Advanced renal cell carcinoma (RCC) following ineffective response to one prior anti-angiogenic therapy.

Pharmacology: Lenvatinib Mesylate is a multikinase inhibitor that hampers the activities of various receptors involved in blood vessel formation and tumor growth, ultimately leading to tumor cell death.

Dosage and Administration: The recommended starting dose is 24 mg orally once a day until disease progression or unacceptable adverse reactions. Dosage adjustments may be necessary based on individual patient factors and tolerability.

Interactions: Lenvatinib may interact with various medications, particularly strong CYP3A4 inhibitors/inducers and drugs affecting stomach acidity. Patients should disclose all medications to their healthcare providers.

Side Effects: Common side effects include high blood pressure, fatigue, diarrhea, reduced appetite, weight loss, protein in urine, and mouth sores. Serious side effects may comprise liver damage, bleeding events, and heart problems.

Precautions and Warnings: Lenvatinib may induce high blood pressure, protein in urine, and heart issues. Patients should undergo regular monitoring for these conditions, along with liver function tests due to potential liver toxicity.

Overdose Effects: If overdose occurs, supportive measures should be administered as there’s no specific antidote. Treatment focuses on managing symptoms.